Ratings & Stock Target Updates on Astronics Corporation (NASDAQ:ATRO) and Ocular Therapeutix, Inc. (NASDAQ:OCUL)

Brokerage firms currently have a positive stance on shares of Astronics Corporation (NASDAQ:ATRO). The majority of analysts covering the equity have either a Buy or Strong Buy recommendation on the stock, yielding a consensus score of 1.80. Those same analysts are projecting that the stock will reach $42.80 on a short term basis.

Astronics Corporation (NASDAQ:ATRO)’s shares may have a significant upside to the consensus target of 42.80, but how has it been performing relative to the market?  The stock’s price is 47.35 and their relative strength index (RSI) stands at 73.96.  RSI is a technical oscillator that shows price strength by comparing upward and downward movements.  It indicates oversold and overbought price levels for a stock.  

Astronics Corporation (NASDAQ:ATRO) shares are moving 15.57% trading at $47.35 today.

Equity Research firms currently have a positive stance on shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL). The majority of analysts covering the equity have either a Buy or Strong Buy recommendation on the stock, yielding a consensus score of 2.10. This is based on the research brokerage reports taken into consideration by Thomson Reuters. Those same analysts are projecting that the stock will reach $20.29 on a short term basis.

Performance
At the time of writing, the stock was trading at $5.60. This represents a change from most recent open price of 13.82%. In terms of performance, year to date, the stock is 25.84%. The monthly stock performance comes in at 31.15%. For the quarter, shares are performing at -7.44%. Weekly performance analysis shows the equity at 14.99%.

Technicals
In taking a look at technical levels, shares are trading 18.81% away from the 50 day simple moving average and -20.21% away from the 200 day simple moving average. Based on a recent bid, the stock is trading -52.50% away from it’s 52- week high and 69.70% away from its 52 week low. After the recent moves, investors may also look to see if the stock has entered oversold or overbought territory and could be ripe for a bounce. As of writing, Ocular Therapeutix, Inc.’s RSI stands at 71.25. In looking at volatility levels, the shares saw weekly volatility of 6.94% and 6.92% over the past month.

Leave a Comment